Barrett's oesophagus, proton pump inhibitors and gastrin: The fog is clearing

Gut

Volumn 59, Issue 2, 2010, Pages 148-149

  Kuipers, Ernst J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; ESOMEPRAZOLE; GASTRIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

BARRETT ESOPHAGUS; CANCER CELL CULTURE; CANCER SUSCEPTIBILITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MEGADOSE; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GASTROESOPHAGEAL REFLUX; HUMAN; INFLAMMATION; LONG TERM CARE; LOW DRUG DOSE; METAPLASIA; NOTE; PRIORITY JOURNAL;

BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; GASTRINS; HUMANS; PROTON PUMP INHIBITORS;

EID: 77149176610     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.191403     Document Type: Note

References (7)

1. van Soest EM, Dieleman JP, Siersema PD, et al. Increasing incidence of Barrett's oesophagus in the general population. Gut 2005; 54:1062-6.
2. Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4: 566-72.
3. Abdalla SI, Lao-Sirieix P, Novelli MR, et al. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res 2004;10:4784-92.
4. Obszynska JA, Atherfold PA, Nanji M, et al. Long-term proton pump inhibition induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo. Gut 2010.
5. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999;45:489-94.
6. Hillman LC, Chiragakis L, Shadbolt B, et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004;180:387-91.
7. El-Serag HB, Aguirre TV, Davis S, et al. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004;99:1877-83.